NeuroBlate System Overview
The NeuroBlate LITT system combines robotic, cooled laser ablation with real-time MRI visualization for brain tumors, epilepsy, and radiation necrosis.

Monteris offers robotic MR-guided laser ablation for brain conditions to surgeons using FullFire and SideFire laser probes.
monteris.comCrawled Oct 21, 2026
The NeuroBlate LITT system combines robotic, cooled laser ablation with real-time MRI visualization for brain tumors, epilepsy, and radiation necrosis.
The NeuroBlate System enables neurosurgeons to perform precise brain lesion ablation.
Access Instructions for Use documentation for the NeuroBlate System, AtamA, Mini-Bolt, and related accessories.
Monteris Medical leads in LITT technology, offering the NeuroBlate NB3 1.6mm laser probe for pediatric and adult minimally invasive neurosurgery.
The page describes NeuroBlate laser ablation as a minimally invasive option for brain tumors and drug-resistant epilepsy, offering patient and family resources.
The NeuroBlate System is a minimally invasive surgical option for brain lesion destruction, with short recovery and minimal stitches.
Defining the Future of LITT with NeuroBlate in Oncology1 Groundbreaking Evidence Published in the Journal of Clinical Oncology — Prospective. Multicenter. Real‑World. For the first time, NeuroBlate LITT outcomes from 787 patients across 25 U.S. centers have been prospectively captured, analyzed, and transformed into actionable clinical evidence. LAANTERN* moves beyond observation — it establishes the standard […]
Access peer-reviewed publications from the LAANTERN prospective registry — the largest real-world dataset on LITT outcomes for brain tumors, epilepsy, and radiation necrosis.
The NeuroBlate NB3 laser probe is the smallest commercially available for brain lesion ablations, featuring cooled technology for versatility in adult and pediatric neurosurgery.
InnovaHealth Partners leads financing with Birchview Capital and Madryn Asset Management, LP, to accelerate commercial, clinical and product development priorities
Monteris Medical Announces First Patient Enrolled in REMASTer Clinical Study on NeuroBlate System for Metastatic Brain Tumor Patients The randomized controlled multicenter study is the first-of-its kind to investigate LITT benefits in radiographically recurrent brain metastasis patients
The American Medical Association accepted Monteris Medical’s application for two new CPT codes for LITT of intracranial lesions with MR imaging guidance.
Monteris Medical published multicenter clinical study results on NeuroBlate System treatment for drug-resistant epilepsy in *Epilepsy Research*, based on the LAANTERN registry.
LITT allows for the prompt cessation of steroids and alleviates symptom burden in brain metastasis patients with radiation necrosis as supported by evidence from 90 patients treated with NeuroBlate laser ablation.
News
Monteris Medical provides neurosurgical technology for physicians and offers career opportunities.
Reimbursement resources for NeuroBlate LITT procedures, including CPT codes, payer coverage information, and billing guidance for hospitals.
The page introduces Monteris Medical’s leadership team and board of directors, who advance minimally invasive neurosurgery.
FIND A PHYSICIAN NeuroBlate is available in the U.S. and Canada only. For additional assistance on finding a NeuroBlate System provider, please contact info@monteris.com. Disclaimers Content of the Physician Finder is provided by and represented as accurate by the listed physicians. Monteris does not warrant the accuracy, completeness, timeliness of the information contained in the […]
NeuroBlate provides published clinical evidence and superior real-time visualization for brain tumors, radiation necrosis, and drug-resistant epilepsy.
Monteris Medical privacy policy, terms of use, and legal notices for monteris.com.
Monteris Medical’s post-market study reveals that the extent of ablation directly influences survival outcomes for brain tumor patients. The findings highlight ablation depth as a critical factor in treatment efficacy. Researchers analyzed real-world data to correlate procedural metrics with patient survival rates.
The **College of Neurological Surgeons (CNS)** has issued clinical guidelines endorsing **laser interstitial thermal therapy (LITT)** as a treatment option for adults with **metastatic brain tumors**. Monteris Medical, a medical technology company, develops LITT systems for minimally invasive neurosurgical procedures. The guidelines reflect growing recognition of LITT’s role in targeted tumor management.
Monteris Medical introduces the NeuroBlate NB3 FullFire 1.6mm laser probe, the smallest commercially available device for brain procedures using laser interstitial thermal therapy (LITT). The probe supports image-guided interventions in neurosurgery. Monteris specializes in advanced laser-based treatments for brain applications.
Monteris Medical secures FDA clearance for its NeuroBlate Fusion-S Software, now commercially available. The software integrates advanced imaging and navigation tools for neurosurgical procedures. The company follows a history of medical device innovations in minimally invasive brain surgery.
Monteris Medical secures $30 million in equity financing to advance its minimally invasive laser systems for treating brain lesions. The company specializes in developing technologies for targeted ablation procedures in neurosurgery. This funding supports further innovation in medical devices for neurological conditions.